June 8, 2024Open Access

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Survodutide is a glucagon/glucagon-like peptide-1 receptor dual agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). We investigated the pharmacokinetic and safety profile of survodutide in people with cirrhosis.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Lawitz et al. (Sat,) studied this question.

synapsesocial.com/papers/68e65879b6db6435875e7d31 https://doi.org/https://doi.org/10.1016/j.jhep.2024.06.003

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis2024 · 431 citations
2Glucagon Receptor Signaling and Lipid Metabolism2019 · 206 citations
3Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database2020 · 28 citations
4Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study2015 · 2,134 citations
5The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis2022 · 2,137 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo